Eve C Feinberg

No ORCID on file · 5 papers in corpus · active 2007-2023

Study types

  • article 3
  • other 1
  • review 1

Condition tags

  • endometriosis 4
  • infertility 2
  • adenomyosis 1
review 2023
Changing the “scope” of diagnosing endometriosis: the new frontier of noninvasive markers
Fertility and sterility ·doi:10.1016/j.fertnstert.2023.12.021
article 2021
Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
F&S reports ·doi:10.1016/j.xfre.2021.05.004

OBJECTIVE: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids. DESIGN…

article 2019
Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women
The Journal of clinical endocrinology and metabolism ·doi:10.1210/clinem/dgz086

CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. OBJECTIVE:…

other 2015
Diminished ovarian reserve is not observed in infertility patients with high normal CGG repeats on the fragile X mental retardation 1 (FMR1) gene
Human Reproduction ·doi:10.1093/humrep/dev220

STUDY QUESTION: Does an association exist between high normal numbers of CGG trinucleotide repeats on the fragile X mental retardation 1 (FMR1) gene and diminished ovarian reserve (DOR)? SUMMARY ANSWER: This large data set demonstrated tha…

article 2007
Infertility surgery is dead: only the obituary remains?
Fertility and sterility ·doi:10.1016/j.fertnstert.2007.02.041